Actively Recruiting
Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)
Led by Central Hospital, Nancy, France · Updated on 2025-06-26
107
Participants Needed
2
Research Sites
7 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
According to Pluvicto® indication, most of patients treated are elderly, with limited/poor venous peripheric access but they received previously chemotherapy through TIVAP and TIVAP generally stays in the body of patients when they are referred for Pluvicto® therapy. This is why TIVAP could be an interesting alternative for administering of 177Lu-PSMA-617. The aim of this study is to assess potential retention of 177Lu-PSMA-617 on TIVAP during administration through in vitro/ex vivo experimentations then in in vivo analysis.
CONDITIONS
Official Title
Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with an injection of Pluvicto as part of the treatment of their prostate cancer, having had a SPECT/CT scan for dosimetry within 2 to 4 hours after injection.
You will not qualify if you...
- Patients who have refused to have their data used for research purposes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHRU de NANCY
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
2
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Research Team
C
Caroline BOURSIER, MD
CONTACT
V
Véronique ROCH, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here